单独评估 LL-37 抗菌肽衍生物以及与万古霉素联合治疗金黄色葡萄球菌。
Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against S. aureus.
机构信息
College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.
Pharmacotherapy Education and Research Center, School of Medicine, The University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
出版信息
J Antibiot (Tokyo). 2018 Nov;71(11):971-974. doi: 10.1038/s41429-018-0090-7. Epub 2018 Aug 17.
Treatment of Staphylococcus aureus infections continues to be a challenge due to antimicrobial resistance. Endogenous antimicrobial peptides may offer a new option for treating S. aureus infections but several factors limit their clinical utility. Herein, we studied the activity of the antimicrobial peptide LL-37 and two truncated derivatives, LL-13 and LL-17 alone and in combination with vancomycin against a range of drug-resistant S. aureus strains including methicillin resistant S. aureus (MRSA) and vancomycin resistant S. aureus (VRSA) strains in vitro. When used with vancomycin, LL-13 and LL-17 displayed synergy against VRSA and showed the ability to restore sensitivity to vancomycin after pretreatment. In addition, LL-13 and LL-17 showed a strong ability to inhibit S. aureus biofilm production. LL-37 derivatives may be useful in treating infections that are resistant to vancomycin or in scenarios where biofilm formation is a concern.
由于抗菌药物耐药性，金黄色葡萄球菌感染的治疗仍然是一个挑战。内源性抗菌肽可能为治疗金黄色葡萄球菌感染提供新的选择，但有几个因素限制了它们的临床应用。在此，我们研究了抗菌肽 LL-37 及其两种截短衍生物 LL-13 和 LL-17 单独和与万古霉素联合治疗多种耐药性金黄色葡萄球菌菌株（包括耐甲氧西林金黄色葡萄球菌（MRSA）和耐万古霉素金黄色葡萄球菌（VRSA）菌株）的体外活性。当与万古霉素联合使用时，LL-13 和 LL-17 对 VRSA 表现出协同作用，并显示出在预处理后恢复对万古霉素敏感性的能力。此外，LL-13 和 LL-17 显示出抑制金黄色葡萄球菌生物膜形成的强大能力。LL-37 衍生物可能对治疗耐万古霉素的感染或在生物膜形成是一个关注点的情况下有用。
Zotero 插件